Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

ViiV planning submissions this year for two-drug HIV regimen

March 15, 2019 5:44 PM UTC

ViiV said it plans to submit regulatory applications this year for a once-monthly two-drug regimen comprising cabotegravir and Johnson & Johnson's Edurant rilpivirine to treat HIV-1 infection.

ViiV Healthcare Ltd. (Brentford, U.K.) disclosed its plans when the company presented detailed data from the open-label Phase III ATLAS and FLAIR trials of the combo as maintenance treatment of HIV-1-infection at the Conference on Retroviruses and Opportunistic Infections in Seattle...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article